Ofatumumab injection is used to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells): in combination with chlorambucil in people who have not received treatment or are unable to receive treatment with fludarabine (Fludara). in combination with fludarabine (Fludara) and alemtuzumab (Campath) when CLL has returned after previous treatment. as extended treatment in people with CLL that has improved fully or partially after at least two lines of treatment. in people who have not responded to treatment with fludarabine (Fludara) and alemtuzumab (Campath). Ofatumumab injection is in a class of medications called monoclonal antibodies. It works by killing cancer cells. Ofatumumab is also available as an injection (Kesimpta) that is used to treat multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control). This monograph only gives information about ofatumumab injection (Arzerra) for treatment of chronic lymphocytic leukemia. If you are receiving ofatumumab for multiple sclerosis, read the monograph entitled Ofatumumab Injection (Multiple Sclerosis).

Related Packages: 00078-0690-61
Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Ofatumumab Injection (Chronic Lymphocytic Leukemia)